Free Writing Prospectus
Filed Pursuant to Rule 433
Registration Statement No. 333-155535
Dated November 18, 2010
 
 
 


    Historical Coupon Amounts for the JPMorgan Alerian MLP Index ETNs (AMJ)

The table below summarizes the coupon amounts for the Alerian MLP Index ETN
during the time periods set forth below.

                                             Coupon
Declaration                        Payment   Amount(1) Current
Date        Ex-Date    Record Date Date      per Note  Yield(2)
11/18/2010  11/24/2010 11/29/2010  12/7/2010 0.4522    5.0%
8/18/2010   8/25/2010  8/27/2010   9/7/2010  0.4509    5.5%
5/18/2010   5/26/2010  5/28/2010   6/8/2010  0.4481    6.0%
2/19/2010   2/25/2010  3/1/2010    3/9/2010  0.4428    6.0%
11/18/2009  11/25/2009 11/30/2009  12/8/2009 0.4431    6.7%
8/19/2009   8/26/2009  8/28/2009   9/8/2009  0.4361    7.3%
5/26/2009   5/27/2009  5/29/2009   6/8/2009  0.4507    8.2%

1) As defined in Amendment No. 8 to Pricing Supplement no. 152, dated October
11, 2010, for the Notes.

2) "Current Yield" equals the current Coupon Amount annualized and divided by
the relevant closing price of the Notes, rounded to one decimal place for ease
of analysis. Except for the coupon determined in May 2009, the relevant closing
price is the closing price of the Notes referenced in the coupon declaration
press release issued for that coupon. For the coupon determined in May 2009 the
relevant closing price is the closing price of the Notes on the trading day
immediately preceding that Declaration Date.

What are the main risks in the ETNs?

The ETNs may result in a loss.

The ETNs are exposed to the credit risk of JPMorgan Chase  and  Co.

The ETNs may not have an active trading market and may not continue to be listed
over their term.

The payment at maturity or upon early repurchase of the ETNs will be based on
the VWAP Level of the Index and not on the closing level of the Index. The VWAP
Level of the Index will most likely differ from the closing level of the Index
or the IIV.

The coupon payments on the ETNs will be variable and may be zero. The Accrued
Tracking Fee reduces the potential coupons and/or the payment at maturity or
upon early repurchase.

The Issuer's obligation to repurchase the ETNs is on a weekly basis, and is
subject to substantial minimum size restrictions. You will not know how much you
will receive upon early repurchase at the time that you elect we repurchase your
ETNs.

The risks identified above are not exhaustive. You should also review carefully
the related "Risk Factors" section of the relevant product supplement and the
"Selected Risk Considerations" in the relevant pricing supplement.

You should read the most recent pricing supplement related to these ETNs dated
October 11, 2010 before you make an investment. You may access this pricing
supplement on the SEC website at www.sec.gov as follows:
http://www.sec.gov/Archives/edgar/data/19617/000089109210004368/e40399_424b2.htm

SEC Legend: JPMorgan Chase and Co. has filed a registration statement (including
a prospectus) with the SEC for any offerings to which these materials relate.
Before you invest, you should read the prospectus in that registration statement
and the other documents relating to this offering that JPMorgan Chase and Co.
has filed with the SEC for more complete information about JPMorgan Chase and
Co. and this offering. You may get these documents without cost by visiting
EDGAR on the SEC Web site at www.sec.gov. Alternatively, JPMorgan Chase and Co.,
any agent or any dealer participating in this offering will arrange to send you
the prospectus and each prospectus supplement as well as any product supplement,
pricing supplement and term sheet if you so request by calling toll-free
800-576-3529.

Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No.
333-155535

To the extent there are any inconsistencies between this free writing prospectus
and the relevant pricing supplement, the relevant pricing supplement, including
any hyperlinked information, shall supersede this free writing prospectus.

Investment suitability must be determined individually for each investor. The
financial instruments described herein may not be suitable for all investors.
This information is not intended to provide and should not be relied upon as
providing accounting, legal, regulatory or tax advice. Investors should consult
their own advisors on these matters.

                                                               November 18, 2010